title: Spondyloarthritis in 2012: Advances in pathogenesis through animal models and imaging.
abstract: Advances in 2012 have helped to solve several established mysteries in spondyloarthritis (SpA) - why T-cell-directed therapies have not delivered the expected efficacy and how the IL-23-IL-17 cytokine axis is linked to the specific pathology of SpA. The opportunity to influence disease progression at inflammatory lesions using anti-TNF agents may be fleeting.
authors.affiliation: Division of Rheumatology, Department of Medicine, 562 HMRB, University of Alberta, Edmonton, Alberta T6G 2S2, Canada. walter.maksymowych@ualberta.ca.
authors.forename: Walter P
authors.initials: WP
authors.lastname: Maksymowych
mesh_terms: D000069594:Abatacept; D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D020381:Interleukin-17 / Q000502:physiology; D053759:Interleukin-23 / Q000502:physiology*; D051379:Mice; D015398:Signal Transduction / Q000502:physiology*; D025241:Spondylarthritis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D018796:Immunoconjugates; D020381:Interleukin-17; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept